MaxCyte, Inc. Director Dealings (7483K)
18 December 2018 - 5:06AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 7483K
MaxCyte, Inc.
17 December 2018
MaxCyte, Inc.
("MaxCyte" or the "Company")
Director Dealings
Issue of equity
Maryland, USA, 17 December 2018 - MaxCyte (LSE: MXCT) the global
cell-based medicines and technology company, announces the issue
and allotment of 34,083 new shares of common stock of 0.1 pence
("New Common Stock") to John Johnston, Non-Executive Director of
the Company, pursuant to the exercise of share options at an
exercise price of 81.5 pence per New Common Stock.
As a result of the above, John Johnston has a beneficial
interest of 120,583 Common Stock, representing 0.2% of the issued
share capital of the Company and a further 54,617 options over
Common Stock.
The New Common Stock will be allocated out of the common stock
the subject of the block listing announced on 2 May 2017. The New
Common Stock will rank pari passu with the existing shares of
common stock of the Company. The total issued stock capital of the
Company following the above will be 51,332,764 shares of common
stock. Shareholders in the Company may use this figure as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the stock capital of the Company.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 ("MAR").
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name John Johnston
======================================== ============================================
2 Reason for the notification
======================================================================================
a) Position/status Non-Executive Director
======================================== ============================================
b) Initial notification/Amendment Initial notification
======================================== ============================================
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
======================================================================================
a) Name MaxCyte, Inc.
======================================== ============================================
b) LEI 54930053YHXULRFCU991
======================================== ============================================
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
======================================================================================
a) Description Ordinary shares of 0.1 pence each
of the financial
instrument,
type of instrument
======================================== ============================================
b) Identification US57777K1060
Code
======================================== ============================================
c) Nature of the Exercise of options over Common Stock
transaction
======================================== ============================================
d) Price(s) and Price(s) Volume(s)
volume(s)
======================================== =========================== ===============
81.5 pence 34,083
========================================================================= ===============
e) Aggregated information N/A (Single Transaction)
- Aggregated
volume
- Price
======================================== ============================================
f) Date of the 17 December 2018
transaction
======================================== ============================================
g) Place of the London Stock Exchange, AIM Market (XLON)
transaction
======================================== ============================================
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Broker
Panmure Gordon
Emma Earl, Freddy Crossley, (Corporate
Finance)
James Stearns (Corporate Broking) +44 (0) 20 7886 2500
Financial PR Adviser
Consilium Strategic Communications
Mary-Jane Elliott +44 (0)203 709 5700
Chris Welsh maxcyte@consilium-comms.com
Sukaina Virji
About MaxCyte
MaxCyte is a global cell-based medicines and life sciences
company applying its patented cell engineering technology platform
to help patients with high unmet medical needs in a broad range of
conditions. MaxCyte is developing novel CARMA therapies for its own
pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for
autologous cell therapy. In addition, through its core business,
the Company leverages its Flow Electroporation(R) Technology
platform to enable its biopharmaceutical industry partners to
advance the development of innovative, cutting-edge medicines,
particularly in cell therapy, including the use of gene editing
tools in the treatment of inherited genetic diseases and
immuno-oncology approaches to treating cancer. The Company has
placed its cutting-edge flow electroporation instruments worldwide,
with all of the top ten global biopharmaceutical companies, has
more than 55 partnered programme licenses in cell therapy including
more than 25 licensed for clinical use. With its robust delivery
technology platform, MaxCyte helps its partners to unlock the full
potential of their products.
For more information, visit www.maxcyte.comFor more information,
visit www.maxcyte.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHFKODPOBDDABD
(END) Dow Jones Newswires
December 17, 2018 13:06 ET (18:06 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024